Fig. 2: Cumulative incidence of non-relapse mortality and relapse in the patients of this study according to the Allo-HCT Refined ELN 2022 risk classification. | Blood Cancer Journal

Fig. 2: Cumulative incidence of non-relapse mortality and relapse in the patients of this study according to the Allo-HCT Refined ELN 2022 risk classification.

From: Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)

Fig. 2

Cumulative incidence of non-relapse mortality and relapse at 2 years (a) and at 5 years (b). 1: Favorable risk, 2: Intermediate Risk, 3: Adverse Risk, 4: Adverse Plus Risk.

Back to article page